CLINICAL TRIALS

Unlocking a new universe of treatment options with degrader-based medicines

CLINICAL TRIALS

Unlocking a new universe of treatment options with degrader-based medicines

Nurix is working expeditiously to translate the science of targeted protein degradation into drug candidates with the potential to become breakthrough therapies.

Relapsed / Refractory B-cell Malignancies

NX-5948

Phase 1A/1B
Administration: Oral
Status: Recruiting
Goal: This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
35 Study Locations

United States

Netherlands

Poland

Spain

United Kingdom

View Study

Relapsed / Refractory B-cell Malignancies

NX-2127

Phase 1A/1B
Administration: Oral
Status: Recruiting
Goal: This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

View Study

Advanced Malignancies

NX-1607

Phase 1A/1B
Administration: Oral
Status: Recruiting
Goal: This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

View Study

Expanded access policy

Consistent with Nurix’s mission to establish degrader-based medicines at the forefront of patient care, we are focused on enrolling and conducting our clinical trials and obtaining the regulatory approvals necessary to make our medicines available to patients as quickly as possible. We are privileged to collaborate with the clinical investigators and patients who participate in our studies to develop new, safe, and effective therapies. We believe this approach will serve patients who could be helped by the therapies we are developing.

Expanded access programs, also known as “pre-approval access” or “compassionate use”, are potential pathways for patients to receive investigational drugs that are not yet approved by the FDA or other regulatory authorities but may be beneficial for patients with serious or life-threatening conditions. Under these programs, patients who are unable to participate in a clinical trial may potentially receive the investigational drug outside of a clinical trial. Under the 21st Century Cures Act, the manufacturer or distributor of one or more investigational drugs for the treatment of one or more serious diseases or conditions shall make available its policy on how it evaluates and responds to requests submitted under section 561(b) of the Federal Food, Drug, and Cosmetic Act for provision of such a drug. The following is Nurix’s policy for responding to requests for expanded access to investigational drugs that are intended to treat serious diseases.

› NX-5948 Expanded Access Policy

For questions about our programs and clinical trials, please contact us.